Over the past decade, the role of Hematopoietic Stem Cell Transplantation (HSCT) as a treatment for Multiple Sclerosis (MS) has gained significant acceptance. Neurologists frequently discuss the therapeutic potential of combining chemotherapy with a stem cell transplant to address the autoimmune aspect of MS, which is believed to be a primary factor leading to demyelination.

During HSCT, a patient initially undergoes immunosuppressive chemotherapy to disable their immune system, followed by an autologous bone marrow aspiration. The aspirate, rich in hematopoetic cells is then reintroduced into the bloodstream. This process is claimed to eliminate autoimmune activity and help rebuild the immune system to prevent further damage. While this method is established in treating blood cancers—using chemotherapy followed by bone marrow transplant to eliminate cancerous cells and rebuild blood cells—its theoretical application to autoimmunity has made its off-label use acceptable to regulatory authorities, particularly given the $25 billion market associated with MS. The proven efficacy of chemotherapy in blood cancer treatment has facilitated sNDA clearance for pharmaceutical companies.

Autoimmunity occurs when the immune system mistakenly attacks the body’s own tissues, often while attempting to eliminate infections. Such immune responses may be one-time events or triggered by recurring infections. This immune action, including cytokine-mediated inflammatory responses, can cause secondary damage to specific tissues, leading to symptoms. The damage may repair over time, but it can also persist as a chronic condition. Simple blood tests, like anti-nuclear antibody (ANA) tests, can indicate if a person is experiencing active autoimmune damage. Despite the effectiveness of chemotherapy and bone marrow transplantation in eradicating cancerous blood, their use in targeting a misbehaving immune system should also be grounded in clinically proven autoimmunity. Currently, the inclusion criteria for HSCT in MS do not include a straightforward test like the ANA test, which could provide valuable insights regarding the appropriateness of HSCT or other immunosuppressive therapies for MS patients. Why, then, is the ANA test overlooked by neurologists when prescribing immunosuppressive treatments without validating the current autoimmune behavior of these patients? The reason may be that the ANA test tends to be negative for most MS patients.

In several studies conducted by Somata Genesis involving individuals diagnosed with Multiple Sclerosis and other autoimmune conditions, it was found that over 90% of subjects tested negative for ANA. A subgroup showed weak-positive ANA results, likely due to secondary immune responses associated with the inflammation that individuals with degenerative conditions often experience. Additional testing with C-reactive protein confirmed heightened inflammation in these subjects, corroborating the weak-positive ANA result. Despite these objective tests indicating autoimmunity and inflammation, they are not included in the criteria before prescribing potentially dangerous immunosuppressive therapies for degenerative conditions that are also prone to infections.

While HSCT is often portrayed as a groundbreaking solution for MS, similar to many other immunosuppressive disease-modifying therapies (DMTs), it tends to be administered to patients in chronic stages of the disease. In these cases, the side effects of increased immunosuppressive doses are often conveniently attributed to the condition itself. The terminology “hematopoietic stem cells” is strategically employed to make the therapy sound more innovative and less harmful than traditional chemotherapy. While hematopoietic cells are naturally present in bone marrow and are regularly released into the bloodstream, their transplantation is necessitated when there is severe damage to the blood that requires rapid rebuilding.

In chemotherapy-induced hemolysis, the transplant is essential to mitigate the primary side effects of chemotherapy. However, since MS is a neurodegenerative disorder, the term “stem cells” is used strategically to suggest regenerative potential, despite the lack of clinical evidence supporting their ability to reverse the primary neurodegenerative damage caused by MS. With this ambiguous nomenclature, “Hematopoietic Stem Cell Transplant” serves as another example of a misrepresented DMT, leveraging the principles of chemotherapy to target Multiple Sclerosis and linking an existing treatment to a previously untapped $25 billion market under the guise of addressing autoimmunity. Ultimately, one must question: Does this treatment truly help MS patients? The clinical rationale does not appear to be well-founded.